Introduction: Edoxaban has been approved for stroke prevention in patients with atrial fibrillation (AF) based on its effectiveness and superior safety compared to warfarin in the controlled ENGAGE AFTIMI 48 trial. The ETNAAF programme was initiated to evaluate the effectiveness and safety of edoxaban in patients under reallife conditions.
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Purpose and methods:
The Global ETNAAF Programme combines data from 3 separate noninterventional prospective ETNAAF registries in Europe, East Asia, and Japan. Data were harmonised, transformed, and integrated into a single database. About 27,000 ETNAAF patients will be included in the registries and followed for ≥2 years. Analyses of this database will allow for an assessment of the risks and benefits of edoxaban in routine clinical care. In this Global ETNAAF Programme first snapshot analysis, baseline data from a large proportion of such patients are presented here. Table 1 shows the Global ETNAAF data for 17,769 edoxabantreated AF patients (66% of total planned enrolled patients from >1,800 centres across 13 countries globally) vs baseline data from patients of the corresponding ETNAAF countries (N=1229) and all the ENGAGE AFTIMI 48 patients in the modified intentiontotreat analysis, randomized to the globally approved highdose edoxaban regimen (N=7012). In Global ETNAAF, 9516 (53.6%) patients were treated with edoxaban 60 mg QD, and 8253 (46.4%) with edoxaban 30 mg QD. Patients in Global ETNAAF were older than those in ENGAGE AFTIMI 48 but had fewer stroke risk factors and more often presented with paroxysmal AF.
Results:

Conclusions:
Compared with ENGAGE AFTIMI 48, the ETNAAF registry enrolled patients with a lower stroke risk and a higher percentage of paroxysmal AF, and a lower proportion of patients with relevant cardiovascular medical history (except for the history of myocardial infarction). We found a balanced distribution of the 60 mg and 30 mg QD dosing at the global level. CrCl, creatinine clearance (CockcroftGault); CHF, congestive heart failure; MI, myocardial infarction; TIA, transient ischemic attack.
